Strategic Acquisition EndoChoice was acquired by Boston Scientific in 2016 for $210 million, indicating strong industry validation and potential for expanded collaboration opportunities within the gastrointestinal medical device market.

Innovative Portfolio With a broad product range including advanced endoscopic imaging systems like Fuse and infection control products, EndoChoice offers multiple upsell and cross-sell opportunities to healthcare providers seeking comprehensive GI solutions.

Growing Customer Base Serving over 2,500 U.S. customers directly and establishing distribution partnerships in 25 countries, EndoChoice provides access to a diverse and expanding international market, presenting opportunities for regional and global sales expansion.

Mid-Market Positioning With revenues estimated between $10M to $25M and around 201-500 employees, EndoChoice is positioned as a mid-size company with significant room for growth, offering tailored solutions to mid-tier healthcare providers and hospitals.

Technology and Digital Presence Utilizing web tools like Google Analytics and professional networks like LinkedIn, EndoChoice actively engages in digital marketing channels, creating avenues for targeted outreach and lead generation in the healthcare technology space.